Suggested recent literature

Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.

These articles are not part of the database yet. Each one is a suggestion. The AI judged it from the title and abstract only and can be wrong. A curator reads the full paper, and only then is it added to CancerImmunoDB. A column on this page shows the curators' decision as soon as there is one.

How the list is made

  1. Search. For every year from 2021 to 2026, PubMed is searched for primary research on cancer drugs together with immune terms, and the 100 best matches of each year are taken. Every PubMed ID comes from PubMed itself, never from the AI.
  2. AI screening. Google Gemini reads each title and abstract and says whether the study tests a named anticancer drug and measures its effect on the immune system, the same scope as the database. In a first check, it marked 33 of 40 articles that curators had already accepted as likely relevant (and 1 as uncertain), and it rejected all 20 unrelated cancer articles.
  3. Curator check. Curators read each suggested paper in full and decide. Accepted papers are entered into the database with their doses, techniques and immune terms.

Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.

574articles screened
360likely relevant
11uncertain
203not relevant
0checked by a curator
0accepted into the database
YearScreenedLikely relevant
20269961
202510081
20249872
20239245
202210052
20218549

Browse the suggestions

Reset Download the full list (CSV)

360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).

PMIDYearArticleDrugsStudy typeCancer typeIn the databaseCurator status
33529880 2021 Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy. Neoplasia (New York, N.Y.) Likely relevant Tests a novel small molecule PD-L1 inhibitor (APBC) in cell-based assays and a mouse model, and measures cytokine secretions and tumor-infiltrating T cells. APBC Mixed cancer APBC 0/0/0 Awaiting curator check
33577301 2021 Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy. ACS applied materials & interfaces Likely relevant Experimentally tests metformin and IR775 liposome nanoparticles in tumour-bearing animals and measures effects on PD-L1 downregulation and T cells. metformin; IR775 Animal bladder and colon cancers metformin 0/0/0; IR775 0/0/0 Awaiting curator check
33617828 2021 Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells. European journal of pharmacology Likely relevant Evaluates the effect of IFN-gamma, a COX-2 inhibitor, and pembrolizumab on cholangiocarcinoma cell lines and their consequent impact on CD8+ T-cell apoptosis. interferon gamma; rofecoxib; pembrolizumab Cell line cholangiocarcinoma interferon gamma 0/0/0; rofecoxib 0/0/0; pembrolizumab 0/0/16 Awaiting curator check
33712445 2021 Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Journal for immunotherapy of cancer Likely relevant Tests HMGB1 inhibitors and immune checkpoint blockade in syngeneic mouse models, measuring changes in various immune cell populations and activation states. HMGB1 inhibitors; anti-PD-1; anti-PD-L1 Animal breast and lung cancer HMGB1 inhibitors 0/0/0; anti-PD-1 14/36/0; anti-PD-L1 0/15/0 Awaiting curator check
33722878 2021 IL-1α Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. Journal of immunology (Baltimore, Md. : 1950) Likely relevant The study experimentally tests rAd.CD40L and anti-PD-L1 in a mouse melanoma model and measures changes in MDSCs, regulatory T cells, cytokines, and PD-L1 expression. rAd.CD40L; anti-PD-L1 Animal melanoma rAd.CD40L 0/0/0; anti-PD-L1 0/15/0 Awaiting curator check
33820821 2021 Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy. Journal for immunotherapy of cancer Likely relevant Patient study analyzing immune cell infiltration, HLA expression, and T cell function after neoadjuvant pembrolizumab treatment. pembrolizumab Patient lung adenocarcinoma pembrolizumab 0/0/16 Awaiting curator check
33826900 2021 Fascin inhibitor increases intratumoral dendritic cell activation and anti-cancer immunity. Cell reports Likely relevant Demonstrates that the fascin inhibitor NP-G2-044 increases intratumoral dendritic cell activation and enhances CD8+ T cell activation when combined with anti-PD-1. NP-G2-044; anti-PD-1 antibody Animal various cancers NP-G2-044 0/0/0; anti-PD-1 antibody 0/2/0 Awaiting curator check
33827976 2021 A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Science translational medicine Likely relevant The study tests a selective HDAC8 inhibitor and anti-PD-L1 therapy in mouse models and measures T cell infiltration, chemokine production, and memory T cell induction. HDAC8 inhibitor; anti-PD-L1 Animal hepatocellular carcinoma HDAC8 inhibitor 0/0/0; anti-PD-L1 0/15/0 Awaiting curator check
33830945 2021 Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. The Journal of clinical investigation Likely relevant The study tests atractylenolide I in mouse CRC models and human organoids, measuring effects on immunoproteasome activity, MHC-I presentation, and CD8+ T cell cytotoxicity. atractylenolide I; immune checkpoint blockade Mixed colorectal cancer atractylenolide I 0/0/0; immune checkpoint blockade 0/1/0 Awaiting curator check
33855973 2021 TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. The Journal of clinical investigation Likely relevant Investigates anti-PD-1/PD-L1 resistance in syngeneic mouse models and measures macrophage polarization and ferroptosis. anti-PD-1; anti-PD-L1 Animal cancer anti-PD-1 14/36/0; anti-PD-L1 0/15/0 Awaiting curator check
33909988 2021 Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Molecular cell Likely relevant Tests anti-CTLA-4 and AMPK agonists in syngeneic mouse models and measures PD-L1 degradation, interferons, and antigen presentation. anti-CTLA-4; AMPK agonists Animal cancer anti-CTLA-4 1/10/7; AMPK agonists 0/0/0 Awaiting curator check
33958794 2021 A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nature medicine Likely relevant The study treats breast cancer patients with anti-PD1 and chemotherapy and investigates intratumoral immune cell changes using single-cell transcriptome, TCR, and proteome profiling. anti-PD1; neoadjuvant chemotherapy Patient breast cancer anti-PD1 1/1/0; neoadjuvant chemotherapy 0/0/0 Awaiting curator check
34103659 2021 PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. Communications biology Likely relevant Evaluates the small molecule immune checkpoint inhibitor CA-170 in immunocompetent mouse tumor models and measures T cell proliferation and activation. CA-170 Animal tumor models CA-170 0/0/0 Awaiting curator check
34119606 2021 Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer. Cancer letters Likely relevant The study tests sonodynamic therapy combined with anti-PD-L1 in a murine model of pancreatic cancer and measures infiltrating CD4+ and CD8+ T-lymphocytes. anti-PD-L1 Animal pancreatic cancer anti-PD-L1 0/15/0 Awaiting curator check
34162872 2021 Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer. Nature communications Likely relevant Examines Notch signaling activation in SCLC cell lines leading to increased APM gene expression and intrinsic tumor immunity. Cell line small cell lung cancer Awaiting curator check
34171309 2021 Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell Likely relevant Tests pharmacologic splicing modulation in tumor-bearing animals and evaluates MHC I immunopeptidome and T cell responses. splicing modulation drugs; checkpoint blockade Animal cancer splicing modulation drugs 0/0/0; checkpoint blockade 0/1/0 Awaiting curator check
34206051 2021 Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors. International journal of molecular sciences Likely relevant Tests combination therapy of alpha-PD-L1 and gemcitabine in a mouse model and measures cytokine levels, MDSCs, M2 macrophages, and cytotoxic T-cell infiltration. alpha-PD-L1 antibody; gemcitabine Animal gastrointestinal tumors alpha-PD-L1 antibody 0/0/0; gemcitabine 30/23/10 Awaiting curator check
34235912 2021 Immune/Hypoxic Tumor Microenvironment Regulation-Enhanced Photodynamic Treatment Realized by pH-Responsive Phase Transition-Targeting Nanobubbles. ACS applied materials & interfaces Likely relevant Demonstrates that a novel nanobubble drug delivery system combining metformin, photodynamic therapy, and PD-L1 blockade reduces immunosuppression and induces antitumor immunity. chlorin e6; metformin; DPPA-1; anti-PD-L1 peptide Cell line triple-negative breast cancer chlorin e6 0/0/0; metformin 0/0/0; DPPA-1 0/0/0; anti-PD-L1 peptide 0/0/0 Awaiting curator check
34266948 2021 Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels. Proceedings of the National Academy of Sciences of the United States of America Likely relevant Tests genetic and pharmacological targeting of Axl combined with anti-PD-1 in a preclinical model, showing normalization of blood vessels and a proinflammatory tumor microenvironment. anti-PD-1 Animal HER2+ breast cancer anti-PD-1 14/36/0 Awaiting curator check
34275267 2021 Injectable Supramolecular Hydrogel for Locoregional Immune Checkpoint Blockade and Enhanced Cancer Chemo-Immunotherapy. ACS applied materials & interfaces Likely relevant The study tests a hydrogel delivering doxorubicin and DPPA-1 peptide in vivo, measuring immunogenic cell death and T-cell-mediated immune responses. doxorubicin; DPPA-1 peptide Animal cancer doxorubicin 22/9/0; DPPA-1 peptide 0/0/0 Awaiting curator check
34433253 2021 Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade. ACS applied materials & interfaces Likely relevant The study experimentally tests chidamide and a PD-L1 inhibitor (BMS-202) on triple-negative breast cancer models, reporting immune readouts such as immunogenic cell death, MHC expression, and T-cell recognition. chidamide; BMS-202 Animal triple-negative breast cancer chidamide 39/2/1; BMS-202 0/0/0 Awaiting curator check
34446607 2021 Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy. Science (New York, N.Y.) Likely relevant The study tests anti-PD-L1 combined with bacterial muropeptides in mouse tumor models and measures immune responses. anti-PD-L1 Animal cancer anti-PD-L1 0/15/0 Awaiting curator check
34479614 2021 Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy. Journal of experimental & clinical cancer research : CR Likely relevant Investigates MET and PD-L1 blockade in pancreatic cancer cell lines and animal models, measuring PD-L1 levels and lymphocyte infiltration. MET inhibitors; PD-1/PD-L1 blockade Mixed pancreatic cancer MET inhibitors 0/0/0; PD-1/PD-L1 blockade 0/1/0 Awaiting curator check
34480981 2021 Effects of exercise and anti-PD-1 on the tumour microenvironment. Immunology letters Likely relevant Experimentally tests anti-PD-1 in tumour-bearing animals and measures its effect on CD8+ T cells in the tumour microenvironment. anti-PD-1 Animal breast cancer and melanoma anti-PD-1 14/36/0 Awaiting curator check
34488792 2021 Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells. Journal of nanobiotechnology Likely relevant The study experimentally tests nanodiamond-doxorubicin conjugates and BMS-1 on cancer cells and TAM models, measuring immune readouts such as M1 macrophage repolarization and HMGB1/PD-L1 regulation. nanodiamond-doxorubicin conjugates; BMS-1 Mixed lung cancer nanodiamond-doxorubicin conjugates 0/0/0; BMS-1 0/0/0 Awaiting curator check
← Previous Page 14 of 15 Next →